TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04636177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Rehabilitation Virtual Reality (PRVR)
Description: Participants will receive approximately 8, 1-hour physiotherapy sessions delivered over the course of 6-12 weeks. Adequate dose: 75% (6 of 8 sessions).
Study: NCT06515470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-9341
Description: Daily oral dose in 28-day cycles until maximum tolerated dose (MTD) or maximum evaluable dose (MED) determined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-9341
Description: Daily oral dose in 28-day cycles until maximum tolerated dose (MTD) or maximum evaluable dose (MED) determined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg intramuscular injections on Day 15 and then every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg intramuscular injections on Day 15 and then every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-9341
Description: Daily oral dose in 28-day cycles using dose determined in Part A
Study: NCT05870917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-BCMA CAR-T
Description: Autologous BCMA-directed CAR-T cells, the double infusion intravenously at a target dose of (2-4)±20％ x 10\^6 anti-BCMA CAR+T cells/kg respectively
Study: NCT05280106

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre-dilution online hemodiafiltration with citrate dialysate
Description: After enrollment, all patients began a 2-week run-in period with conventional dialysis fluid containing acetate and the lowest dose of unfractionated heparin. The investigator titrated the heparin dose by reducing the dose step by step, 25% in each step, until the final minimal dose was achieved. The experimental study consisted of 3 phases, 4 weeks in each phase, and the phases were separated by 1-week washout periods. Phase 1 used CD with 50% of the heparin dose of the baseline. Phases 2 and 3 used 25% heparin and no heparin, respectively. New dialyzers were introduced at the beginning of each phase and the heparin dose was resumed during the washout phase. The calcium concentration in the dialysis fluid was kept constant (1.5 mmol/L) to allow evaluation of the effect of CD on calcium balance
Study: NCT04620252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricalcium phosphate supplement
Description: Chewable tricalcium phosphate supplement, chewed for 30 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium carbonate supplement
Description: Chewable calcium carbonate supplement, chewed for 30 seconds.
Study: NCT05280106

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-dilution hemodiafiltration with citrate dialysate
Description: same protocol with post-dilution Ol-HDF in these same patients for the later 12 weeks.
Study: NCT05774184

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: barzolvolimab
Description: subcutaneous administration
Study: NCT04723550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hospital telemedicine management system
Description: Patients upload data of blood glucose, diet and exercise. Then doctors guide patients' diet, exercise and medication adjustment through the telemedicine system.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Outpatient/telephone follow-up：continued care, as usual, from their primary care provider through out duration of action 6 months intervention period
Study: NCT04620252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium citrate supplement
Description: Chewable calcium citrate supplement, chewed for 30 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inactive supplement and fluoride mouthwash
Description: A chewable candy chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium carbonate supplement and fluoride mouthwash
Description: A calcium carbonate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium citrate supplement and fluoride mouthwash
Description: A calcium citrate supplement chewed for 30 seconds, immediately followed by a 1 minute rinse with an over the counter sodium fluoride mouthwash, at a concentration of 0.05% (226 parts per millim (ppm) of fluoride).
Study: NCT04546451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music practice
Description: Patients will be trained to play a simple instrument (tongue-drum) in a group setting using different musical styles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychomotor therapy
Description: Patients will be trained in body awareness and a wide range of of movement activities.
Study: NCT06050941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Idarubicin 6mg/m2 d5-7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 60mg/m2 d5-9
Study: NCT04696016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin conductance guided antinociception
Description: The value of skin conductance guides the titration of sufentanil

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care antinociception
Description: The intensive care team titrates antinociception based on their standard approach (using a clinical approach by assessing blood pressure, heart rate, and ventilator dyssynchrony).
Study: NCT05774184

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: subcutaneous administration
Study: NCT06216899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-food based smoothie
Description: The smoothies will be based upon the concept of reverse-engineering of exclusive enteral nutrition and provide 100% of calculated caloric needs for weeks 0-4. At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formula
Description: Conventional formula (Boost, Ensure, Modulen) as per the direction of their primary Gastroenterology team to provide 100% of calculated caloric needs for weeks 0-4. At week 4, select foods will be introduced to provide up to 20% of daily caloric needs.
Study: NCT05791994

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visual cognitive stimulation exercises
Description: Patients included in Intervention group will receive a 30-minute session of complex visual stimuli on a touch screen (3 10-minute exercises : saccade exercises, then pursuit exercises, then matching exercises) every other day for 30 days, with increasing difficulty of the exercises as the sessions progress.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Broadcast of a television program
Description: Patients included in Comparator group will watch a 30-minute television program (Allô Docteurs) on a touch screen every other day for 30 days.
Study: NCT06492174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AGENT DCB 40 mm
Description: Drug coated PTCA balloon catheter 40 mm size
Study: NCT06443684

Intervention type: DIAGNOSTIC_TEST
Intervention: MRD
Description: MRD（LC-10）include 10 lung cancer-related driver gene mutation site

Intervention type: DIAGNOSTIC_TEST
Intervention: MRD
Description: MRD（LC-10）include 10 lung cancer-related driver gene mutation site

Intervention type: DIAGNOSTIC_TEST
Intervention: MRD
Description: MRD（LC-10）include 10 lung cancer-related driver gene mutation site
Study: NCT06489704

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Echocardiography will be performed according to clinical standards
Study: NCT05469243

Intervention type: DRUG
Intervention: Psychedelic
Description: retrospective survey of previous use
Study: NCT04798274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Theta Burst Stimulation
Description: Continuous theta burst stimulation (cTBS) will be applied using a MagPro X100 (MagVenture, Inc. Alpharetta, GA). The cTBS protocol consists of bursts of three pulses of 50 Hz stimulation repeated at 200 ms intervals (5 times per second) for 40 seconds (for a total of 600 pulses). Stimulation will be applied at an intensity of 80% of active motor threshold (AMT). Brainsight (Rogue Research) frameless neuronavigation system will be used to target the specific structural MRI-defined region of stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Continuous Theta Burst Stimulation
Description: Continuous theta burst stimulation (cTBS) will be applied using a MagPro X100 (MagVenture, Inc. Alpharetta, GA). The cTBS protocol consists of bursts of three pulses of 50 Hz stimulation repeated at 200 ms intervals (5 times per second) for 40 seconds (for a total of 600 pulses). Stimulation will be applied at an intensity of 80% of active motor threshold (AMT). Brainsight (Rogue Research) frameless neuronavigation system will be used to target the specific structural MRI-defined region of stimulation.
Study: NCT05840055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy is one potential intervention for reducing internalizing symptoms, increasing purpose in life, and reducing avoidance-based coping among people with NMOSD and their caregiver loved ones. ACT is a third wave behavioral therapy which balances encouraging life changes in the service of one's values (purpose in life) with a strong acceptance component. This novel, experiential, contextual talk therapy is an empirically supported treatment for anxiety and depression, substance use, and has proven successful in managing chronic pain, somatic problems, HIV, Pancreatic Cancer and Cystic Fibrosis.
Study: NCT04709601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hiprex
Description: Patients with negative urine culture will be prescribed Hiprex 1 g PO BID x 1 yr and patients with a positive urine culture will be prescribed antibiotics.
Study: NCT05666310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Half of study participants will randomly receive denosumab 60 mg subcutaneous injection at month 0 and 6 with zoledronic acid placebo at month 0.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Half of study participants will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 with denosumab placebo at month 0 and 6. All forty participants will receive zoledronic acid 5 mg intravenous infusion at month 12.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab Placebo
Description: Half of study participants who will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 will also receive denosumab placebo at month 0 and 6.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid Placebo
Description: Half of study participants who will randomly receive denosumab 60 mg subcutaneous injection at month 0 and 6 will also receive zoledronic acid placebo.
Study: NCT06225739

Intervention type: OTHER
Intervention: Electronic pregnancy register
Description: Electronic pregnancy register will be created based on local ANC register to monitor pregnancy outcomes across all sites. Pregnant women of all ages attending antenatal care (ANC) facility will be registered

Intervention type: OTHER
Intervention: In-depth interviews and focus group discussions
Description: In-depth interviews (IDIs) and focus group discussions (FGDs) will be used to assess the user experience and the perceptions of pregnant women and health workers on the feasibility, usability, and acceptability of open-source mobile applications for tracking pregnancy outcomes

Intervention type: OTHER
Intervention: In-depth interviews and focus group discussions
Description: In-depth interviews (IDIs) and focus group discussions (FGDs) will be used to assess the user experience and the perceptions of pregnant women and health workers on the feasibility, usability, and acceptability of open-source mobile applications for tracking pregnancy outcomes
Study: NCT05024929

Intervention type: PROCEDURE
Intervention: Whole body scan
Description: Patients will receive oncogene-specific molecularly targeted therapy independently of this protocol either via commercial supply of an FDA approved agent, or as part of a separate therapeutic clinical trial/compassionate use protocol/single patient investigational new drug (IND).~During screening, patients will undergo a baseline RAI-whole body scan (WBS) to assess RAI-avidity of their tumor per standard of care. Following approximately 28 days of targeted therapy, the WBS will be repeated to determine whether this therapy is associated with an increase in RAI-avidity of their tumor.
Study: NCT05201014

Intervention type: DIAGNOSTIC_TEST
Intervention: NT-pro-BNP
Description: Blood draw

Intervention type: DIAGNOSTIC_TEST
Intervention: NT-pro-BNP
Description: Blood draw

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram
Description: electrodes are placed on certain spots and a reading obtained to measure the voltage of the heart

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram
Description: electrodes are placed on certain spots and a reading obtained to measure the voltage of the heart

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: medical imaging of the heart

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: medical imaging of the heart
Study: NCT06494683

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pueraria lobata radix
Description: The dose of Pueraria lobata radix granules is one sachet per day, 1.5g per sachet, which equivalent to 15 g of the original herb.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pueraria lobata radix
Description: The dose of Pueraria lobata radix granules is one sachet per day, 1.5g per sachet, which equivalent to 15 g of the original herb.
Study: NCT04258345

Intervention type: OTHER
Group type: OTHER
Intervention: ASB Feeding Study
Description: Participants will undergo a washout period and then scheduled for blood draw after which ASB feeding period will begin followed by a second blood draw.
Study: NCT05520515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Land Training Plus Health Education
Description: Participants perform a 12-week training program with two weekly exercise sessions on non-consecutive days. Sessions last 45 min (5 min of warm-up, 35 min of exercise, and 5 min of stretching) throughout the intervention period. The intervention occurs at the School of Physical Education, Federal University of Pelotas. Depending on weather conditions, the land training group will perform aerobic training with walking/running exercises in a flat outdoor environment or inside a multi-sport gym. The training session will be collective, with 3 to 6 participants, supervised by two experienced instructors, one at the starting point and the other following the movement of the participants. In addition, the group receives the booklet and the offer of weekly meetings of an educational program (30 min before one of the training sessions) with the same interactive lectures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: The intervention occurs at the School of Physical Education, Federal University of Pelotas. The intervention consists of an educational program with weekly lectures of approximately 30 min. The lectures are led by a qualified health professional, using expository and interactive approaches on topics that cover basic knowledge related to breast cancer and complementary therapies. Additionally, each participant receives a self-care booklet containing information about the topics addressed during the meetings. Qualified professionals give lectures on the following topics: 1) fatigue and quality of life; 2) anxiety and depressive symptoms; 3) body image and sexual function; 4) self-esteem; 5) self-care; 6) sleep; 7) cognitive function; 8) symptoms in the arm and breast; 9) pain and arthralgia; 10) body composition and bone health; 11) eating habits; 12) physical activity.
Study: NCT05356455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interview technique
Description: Difference between pre-test and post-test
Study: NCT06441617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Online Therapy for Fatigue
Description: An MS-specific fatigue management program, delivered as a stand-alone, fully automated intervention via an internet-browser.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Online Therapy for Fatigue
Description: An MS-specific fatigue management program, delivered as a stand-alone, fully automated intervention via an internet-browser.
Study: NCT05930431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity variety intervention
Description: The counseling in the variety condition will serve many purposes. The first session will concentrate on informing participants on the importance of having variety in their physical activity routine and how to access the variety of physical activities available to them. The variety condition will be instructed to complete at least three different HIIT workouts per week. They will be encouraged to complete more than three workouts. The following counseling sessions will be provided to not only continue supporting variety in physical activity but also to support participants' basic psychological needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity consistency comparison condition
Description: The counseling in the consistency condition will serve many purposes. The first session will concentrate on informing participants the importance of having consistency in their physical activity routine and how to access the HIIT workout available to them. The consistency condition will be instructed to complete the provided HIIT workout three times per week. They will be encouraged to complete more than three workouts. The following counseling sessions will be provided to not only continue supporting consistency in physical activity but also to support participants' basic psychological needs.
Study: NCT06224439

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hypobaric spinal anaesthesia
Description: 0.5% Bupivacain and distilled water with bupivacaine hydrochloride active ingredient will be applied in the range of 2-4cc according to the patient's height and weight.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumbar plexus block
Description: ultrasound and nerve stimulator will be used for lumbar plexus block
Study: NCT05704907

Intervention type: OTHER
Group type: OTHER
Intervention: gallbladder ultrasound
Description: gallbladder ultrasound
Study: NCT06584032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib
Description: Fruquintinib will be orally administrated once daily for 2 consecutive weeks followed by a 1-week break.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: Sintilimab will be intravenously administrated on Day 1 every three weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 175 mg/m\^2 via IV infusion, once a week for 3 weeks followed by a 1-week break.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: 60mg/m\^2 via IV infusion, on Day 1 every three weeks.
Study: NCT06135636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Direct verbal and written education at the time of enrollment on cocooning and recommendation for partner Tdap vaccination prior to delivery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Direct verbal and written education at the time of enrollment on cocooning and recommendation for partner Tdap vaccination prior to delivery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine administration
Description: Option to receive Tdap at their convenience at the WIH obstetric care clinic provided to participant
Study: NCT05289193

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Patients will have a baseline CD8 PET scan prior to receiving one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection of Melanoma
Description: Patients will have a baseline CD8 PET scan prior to one dose of neoadjuvant nivolumab~1mg/kg + ipilimumab 3mg/kg. After 4 weeks, patients will have a repeat CD8 PET scan and then undergo surgical resection of their stage III melanoma.
Study: NCT05660967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Epcoritamab will be administered by subcutaneous (SC) injections in 28-day cycles for up to 12 cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Epcoritamab will be administered by subcutaneous (SC) injections in 28-day cycles for up to 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally (capsules; starting dose of 10 or 20 mg) once daily on Day 1 to Day 21 of each 28-day cycle for up to 12 cycles.
Study: NCT06449599

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: local anesthesia 400 mg prilocaine (priloc 2%, 20 ml, Vemilac,Türkiye) to surgical field and additionally ultrasound-guided rhomboid intercostal plane block 0,25% bupivacaine 20 ml (Buvasin 0,5%, 20 ml, Vemilac, Türkiye) will be applied to the patients who will be inserted implantable cardioverter defibrillator.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: parenteral local anesthesia
Description: only local anesthesia 400 mg prilocaine (priloc 2%, 20 ml, Vemilac,Türkiye) to surgical field will be applied to the patients who will be inserted implantable cardioverter defibrillator.
Study: NCT05511363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KarXT
Description: KarXT 20 mg/2 mg TID KarXT 30 mg/3 mg TID KarXT 40 mg/4 mg TID KarXT 50 mg/5 mg TID KarXT 66.7/6.67 mg TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsules